Now, SII seeks trial approval for Novavax Covid vaccine - Hindustan Times
close_game
close_game

Now, SII seeks trial approval for Novavax Covid vaccine

By, New Delhi
Jan 31, 2021 04:14 AM IST

SII is currently manufacturing Covishield, which has been developed by the University of Oxford and AstraZeneca and is one of the two coronavirus vaccines approved in the country.

The Serum Institute of India (SII) has applied to start trials of another Covid-19 vaccine, hoping to launch it by June this year, the firm’s chief executive officer Adar Poonawalla said on Saturday.

SII has applied to India’s drugs controller for permission to conduct a small bridging study for Novavax’s Covid-19 vaccine candidate.(Reuters)
SII has applied to India’s drugs controller for permission to conduct a small bridging study for Novavax’s Covid-19 vaccine candidate.(Reuters)

SII is currently manufacturing Covishield, which has been developed by the University of Oxford and AstraZeneca and is one of the two coronavirus vaccines approved in the country.

Hindustan Times - your fastest source for breaking news! Read now.

“Our partnership for a Covid-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!,” Poonawalla tweeted. SII has applied to India’s drugs controller for permission to conduct a small bridging study for Novavax’s Covid-19 vaccine candidate. A bridging trial is a supplementary assessment performed in a new region or country to get more clinical data on efficacy, safety and dose regimen.

Novavax has announced that its vaccine was effective in big trials in the UK and South Africa, though its effectiveness appeared to be reduced in South Africa, where a mutation is prevalent. It announced that NVX-CoV2373, its protein-based vaccine candidate, had the efficacy of 89.3% in its Phase 3 clinical trial conducted in the UK.

The Drugs Controller General of India (DCGI), VG Somani, and a committee of subject experts at the Central Drugs Standard Control Organisation (CDSO) are in the process of examining the application, according to a person aware of the developments.

(With agency inputs)

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! - Login Now!
SHARE THIS ARTICLE ON
Share this article
  • ABOUT THE AUTHOR
    author-default-90x90

    Rhythma Kaul works as an assistant editor at Hindustan Times. She covers health and related topics, including ministry of health and family welfare, government of India.

SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, February 27, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On